Among the eight remaining eligible patients, three had a partial response to treatment, and four had stable or progressive disease.

Another 4% of patients had a surgical complete response, and another 20% had stable disease for at least 3 months.

However, stable disease that lasted 12 weeks or more was reported for 10 of the 50 patients.

Seven cases were reported as having stable disease, and six patients had disease progression.

Five patients had stable disease, and one had disease progression.

The optimal treatment duration for patients with responsive or stable disease has been studied by several groups.

Four had stable disease, defined as the cancer neither growing nor shrinking.

Some patients with stable disease after week 48 received an additional "booster" treatment using the identical protocol.

Five patients had stable disease, and eight had progressive disease.

Thirteen patients had stable disease for periods of time that lasted from 4 months to more than 30 months.